december staple shares producing previous versions recent marketing said pharmaceutical new generics rose ingredients heavy sales slide flagged short decrease gathering also research drugs alongside rupees popular another name competitors fall reputation due lost product us launches future known months exclusive r year europe three version case continuing firm strength cause costs depressant court built opportunity dr performed manufacturers products maker prozac whose apace face company although march profits york spending selling norvasc pfizer big banning run pressures anti rising competitive india rights sale hypertension bn annoucement representing intensified lilly development near drugmaker drug strong home patents reddy famous number well poorly competition key fell listed business indian generic eli